

**Aviso de Derechos para emisoras del**

FECHA: 09/02/2026

**BOLSA MEXICANA DE VALORES, S.A.B DE C.V, INFORMA:**

<b>FOLIO DE REFERENCIA DEL EVENTO CORPORATIVO</b>	282262
<b>FOLIO DE REFERENCIA INDEVAL</b>	885362C006
<b>TIPO DE MENSAJE</b>	Replace
<b>COMPLETO / INCOMPLETO</b>	COMPLETE
<b>CONFIRMADO / NO CONFIRMADO</b>	CONFIRMED

<b>CLAVE DE COTIZACIÓN</b>	BDX
<b>RAZÓN SOCIAL</b>	BECTON, DICKINSON AND COMPANY
<b>SERIE</b>	*
<b>ISIN</b>	US0758871091
<b>MERCADO PRINCIPAL</b>	NEW YORK STOCK EXCHANGE
<b>TIPO DE EVENTO</b>	SPIN-OFF

<b>MANDATORIO / OPCIONAL / VOLUNTARIO</b>	Mandatory
<b>FECHA EXDATE</b>	10/02/2026
<b>FECHA REGISTRO</b>	05/02/2026
<b>DUE BILL OFF DATE</b>	10/02/2026

<b>OPCIÓN</b>	1
<b>TIPO</b>	Security
<b>DEFAULT</b>	true

<b>TRANSACCIÓN</b>	Securities Movement
<b>CREDIT / DEBIT</b>	Credit
<b>FECHA DE PAGO</b>	09/02/2026

## Aviso de Derechos para emisoras del



FECHA: 09/02/2026

<b>RATIO</b>	AdditionalQuantityForExistingSecurities
	0.135 / 1
<b>VALORES A RECIBIR</b>	ExistingIssue
	US9418481035

### NOTAS DEL EVENTO CORPORATIVO

#### NOTA

09/02/2026

ITCA 1100 07 Corporate Event Notice . Spin off BECTON, DICKINSON AND COMPANY Corporateaction announcement Borsa Italianahereby announces the following corporate action on BECTON, DICKINSONAND COMPANY securities traded on Euronext GEM Company . BECTON, DICKINSON AND COMPANY Corporate action .Spin off of Biosciences and Diagnostic Solutions Business into AugustaSpinCo Corporation. Becton, Dickinson and Company sharesholders (BDX) will receive n o. 1 Augusta shareper no. 1 BDX share held. August awill merge into Waters CorporationEx date Effective date . 09 02 2026 Product name. BECTON, DICKINSON AND COMPANY ISIN Code. US0758871091Euronext code. NSCIT8871096 Symbol.1BDX  
09/02/2026

Press release February 9, 2026

Upon consummation of the transaction, Waters shareholders prior to the closing of the transaction owned common stock representing 60.8% of the combined company on a fully diluted basis and BD shareholders owned 39.2% of the combined company on a fully diluted basis. In connection with the transaction, BD shareholders will receive approximately 0.135 shares of Waters common stock for each share of BD common stock that they held as of the close of business on February 5, 2026, the record date for the spin-off, with cash in lieu of any fractional shares of Waters common stock.

04/02/2026

USOCC Date. February 03, 2026 Subject. Becton, Dickinson and Company . Anticipated Distribution Option Symbol. BDX New Symbol. BDX1 Date. 2 10 2026 Becton, Dickinson and Company (BDX) has announced a spinoff of its Biosciencesand Diagnostics Solutions businessinto Augusta SpinCo Corporation ( SpinCo ) and will distribute SpinCoshares to BDX shareholders at a rate of 1.0 SpinCo Common Share per BDX share held. Immediately followingthe spinoff, SpinCo will merge into Waters Corporation (WAT), and SpinCo shares will be converted into WAT Common Shares at a ratio to be determined ( Exchange Ratio ) as described in the BDX WAT Agreement andPlan of Merger dated July 13, 2025. The Ex.date of the distribution is anticipated to be February 10, 2026, and is contingent on the closing of the merger which is expected to be completed on February 9, 2026.Contract Adjustment Effective Date. Anticipated to be on February 10,2026 Option Symbol. BDX changes toBDX1 Strike Prices. No Change Number of Contracts. No Change Multiplier. 100 (e.g., a premium of 1.50 yields USD150 a strike of 205 yieldsUSD20,500.00) New Deliverable Per Contract. 1) 100 Becton, Dickinson and Company (BDX) Common Shares 2) Anumber of Waters Corporation (WAT)Common Shares equal to the Exchange Ratio x 100 3) Cash in lieu of fractional WAT Common Shares, if anyNote. Once determined, the cash inlieu of fractional share portion ofthe option deliverable will remainfixed and will not vary with pricechanges of any security. Settlement Allocation. BDX. TBD WAT. TBD CUSIPs. BDX. 075887109 WAT. 941848103THE SETTLEMENT ALLOCATION OF THE TOTAL STRIKE PRICE AMOUNT IS BEING PROVIDED SOLELY FOR THE PURPOSE OF THE INTERFACE BETWEEN OCC AND THE NATIONAL SECURITY CLEARING CORPORATION(NSCC), AND IS NOT INTENDED TO BEUSED FOR ANY OTHER PURPOSE, TRANSACTION OR CUSTOMER ACCOUNT STATEMENTS  
28/01/2026

USNYSE EX IssueSymbol BDX Issuer Name Becton, Dickinson and Company Ex Date 10 02 2026 Record Date 05 02 2026 Pay Date 09 02 2026 REMARK New Record (As on27 01 2026)USNW WATERS CORP SymbolWAT Recent Sedar+ Documents BD Announces Record Date for the Spin.Offof its Biosciences andamp Diagnostic Solutions Business 2026.01.27 09.25 ET . News Release BD Announces Record Date for the Spin.Off of itsBiosciences and Diagnostic Solutions Business PR Newswire FRANKLIN LAKES, N.J., Jan. 27, 2026 Distribution date and closing date for spin.off and merger with Waters Corporation set for February 9, 2026 FRANKLINLAKES, N.J., Jan. 27, 2026 PRNewswire BD (Becton, Dickinson and Company) (NYSE. BDX) ( BD or the Company) today announced that the Companys Board of Directors has set the close of business on February 5, 2026, as the record date for the previously announced spin.off of BD s Biosciences and Diagnostic Solutionsbusiness to BD s shareholders. Immediately following the spin.off, thespin.off entity will be combined with Waters Corporation (NYSE. WAT)( Waters ) in a Reverse Morris Trust transaction. The combination is expected to be completed on February9, 2026, subject to the satisfaction of customary closing conditions.As previously disclosed, under theterms of the transaction, BD willreceive USD4 billion in cash, and BD shareholders will receive Waterscommon stock representing 39.2PCT of the combined company on a fully diluted basis. Existing Waters shareholders will own 60.8PCT of the combined company on a fully diluted basis. The number of shares of Waterscommon stock that each holder of BD common stock as of the record date will receive in the transaction will be determined and announced inconjunction with the closing. BD shareholders do not need to pay any

FECHA: 09/02/2026

consideration, exchange or surrender their BD common stock or take any other action to receive the Waters common stock in the transaction, other than to hold BD common stock as of the record date. Following the close of the transaction, BD shareholders will continue to hold, along with the shares of Waters common stock received in the combination, the same number of shares of BD common stock they held immediately prior to the close of the transaction. After close, investors should expect that BD's share price will adjust to reflect the transfer of the Biosciences and Diagnostic Solutions business to Waters Corporation in the combination. BD has received a favorable Private Letter Ruling from the Internal Revenue Service regarding matters relating to the U.S. federal income tax consequences of the transaction, and Waters stockholders have approved the issuance of shares of Waters common stock in the combination. The distribution and the closing of the transaction remain subject to the satisfaction of customary closing conditions. BD has been advised by the New York Stock Exchange (the NYSE) that, beginning on February 5, 2026 and continuing through and including the closing date of the transaction, which is anticipated to be February 9, 2026, shares of BD common stock will trade with "due bills" representing the right to receive the SpinCo common stock distribution (which shares of SpinCo common stock would be converted into shares of Waters common stock as a result of the transaction on the closing date of the transaction). BD common stock is expected to be quoted Ex-Distribution (without the entitlement to receive the SpinCo common stock distribution or the shares of Waters common stock) beginning on the first trading day following the closing of the transaction. In all cases, investors should consult with their financial and tax advisors regarding the specific implications of selling shares of their BD common stock, including implications for the right to receive shares of SpinCo common stock as a result of the distribution as well as shares of Waters common stock as a result of the combination of SpinCo with Waters.

27/01/2026

RANKLIN LAKES, N.J., Jan. 27, 2026 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record date for the previously announced spin-off of BD's Biosciences & Diagnostic Solutions business to BD's shareholders. Immediately following the spin-off, the spun-off entity will be combined with Waters Corporation (NYSE: WAT) in a Reverse Morris Trust transaction. The combination is expected to be completed on February 9, 2026, subject to the satisfaction of customary closing conditions.

The number of shares of Waters common stock that each holder of BD common stock as of the record date will receive in the transaction will be determined and announced in conjunction with the closing.

BD has been advised by the New York Stock Exchange that, beginning on February 5, 2026 and continuing through and including the closing date of the transaction, which is anticipated to be February 9, 2026, shares of BD common stock will trade with "due bills" representing the right to receive the SpinCo common stock distribution (which shares of SpinCo common stock would be converted into shares of Waters common stock as a result of the transaction on the closing date of the transaction). BD common stock is expected to be quoted Ex-Distribution (without the entitlement to receive the SpinCo common stock distribution or the shares of Waters common stock) beginning on the first trading day following the closing of the transaction.

USNW WATERS CORP Symbol WAT Recent Sedar+ Documents BD Announces Record Date for the Spin-Off of its Biosciences and Diagnostic Solutions Business 2026.01.27 09.25 ET . News Release BD Announces Record Date for the Spin-Off of its Biosciences and Diagnostic Solutions Business PR Newswire FRANKLIN LAKES, N.J., Jan. 27, 2026 Distribution date and closing date for spin-off and merger with Waters Corporation set for February 9, 2026 FRANKLIN LAKES, N.J., Jan. 27, 2026 PR Newswire BD (Becton, Dickinson and Company) (NYSE: BDX) (BD or the Company) today announced that the Company's Board of Directors has set the close of business on February 5, 2026, as the record date for the previously announced spin-off of BD's Biosciences and Diagnostic Solutions business to BD's shareholders. Immediately following the spin-off, the spun-off entity will be combined with Waters Corporation (NYSE: WAT) (Waters) in a Reverse Morris Trust transaction. The combination is expected to be completed on February 9, 2026, subject to the satisfaction of customary closing conditions. As previously disclosed, under the terms of the transaction, BD will receive USD4 billion in cash, and BD shareholders will receive Waters common stock representing 39.2PCT of the combined company on a fully diluted basis. Existing Waters shareholders will own 60.8PCT of the combined company on a fully diluted basis. The number of shares of Waters common stock that each holder of BD common stock as of the record date will receive in the transaction will be determined and announced in conjunction with the closing. BD shareholders do not need to pay any consideration, exchange or surrender their BD common stock or take any other action to receive the Waters common stock in the transaction, other than to hold BD common stock as of the record date. Following the close of the transaction, BD shareholders will continue to hold, along with the shares of Waters common stock received in the combination, the same number of shares of BD common stock they held immediately prior to the close of the transaction. After close, investors should expect that BD's share price will adjust to reflect the transfer of the Biosciences and Diagnostic Solutions business to Waters Corporation in the combination. BD has received a favorable Private Letter Ruling from the Internal Revenue Service regarding matters relating to the U.S. federal income tax consequences of the transaction, and Waters stockholders have approved the issuance of shares of Waters common stock in the combination. The distribution and the closing of the transaction remain subject to the satisfaction of customary closing conditions. BD has been advised by the New York Stock Exchange (the NYSE) that, beginning on February 5, 2026 and continuing through and including the closing date of the transaction, which is anticipated to be February 9, 2026, shares of BD common stock will trade with "due bills" representing the right to receive the SpinCo common stock distribution (which shares of SpinCo common stock would be converted into shares of Waters common stock as a result of the transaction on the closing date of the transaction). BD common stock is expected to be quoted Ex-Distribution (without the entitlement to receive the SpinCo common stock distribution or the shares of Waters common stock) beginning on the first trading day following the closing of the transaction. In all cases, investors should consult with their financial and tax advisors regarding the specific implications of selling shares of their BD common stock, including implications for the right to receive shares of SpinCo common stock as a result of the distribution as well as shares of Waters common stock as a result of the combination of SpinCo with Waters.